EUCREAS

The actual benefit of EUCREAS/ICANDRA is substantial in the extension of the Marketing Authorisation indication "in combination with a sulfonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulfonylurea".

The Transparency Committee considers that EUCREAS/ICANDRA does not provide any improvement in actual benefit (level V, non-existent) in the treatment of patients with type 2 diabetes in oral triple therapy in combination with a sulfonylurea.